Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis

    Hemodialysis International Date published:

  • Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

    American Heart Journal Date published:

  • Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program

    Endocrinology, Diabetes & Metabolism Date published:

  • Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

    Diabetes, Obesity and Metabolism Date published:

  • The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

    Kidney International Date published:

  • Innovating and invigorating the clinical trial infrastructure for glomerular diseases

    Kidney International Date published:

  • Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

    Metabolism Date published:

  • An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

    International Journal of Cardiology Date published:

  • Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

    ESC Heart Failure Date published:

  • Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

    Kidney International Reports Date published:

  • Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    American Journal of Kidney Diseases Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW

    Date published:

  • MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL

    Date published:

  • The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

    Diabetes, Obesity and Metabolism Date published: